Skip to content

A study for understanding the effect of FENO for guidance of the stepping down treatment of controlled asthma

A study for understanding the effect of FENO for guidance of the stepping down treatment of controlled asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16009860
Enrollment
Unknown
Registered
2016-11-14
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

1:stepping down of asthma medication

Sponsors

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. adult asthma patient diagnosed at least two years previously; 2. regular treatment with inhaled corticosteroids and long-acting beta-agonists for at least 6 months 3. no changes in regular anti-asthma medication within 6 months; 4. asthma is well controlled (all conditions must be fulfilled): (1) No courses of oral corticosteroids due to asthma within one year; (2) No hospital admissions due to asthma within one year; (3) Juniper's Asthma Control Questionnaire score equal or less than 0.75.

Exclusion criteria

Exclusion criteria: 1. The presence of another chronic respiratory disease in addition to asthma. Such diseases include moderate to severe polypotic chronic rhinosinusitis, chronic obstructive pulmonary disease, sarcoidosis, and cystic fibrosis presence of severe co-morbidity; 2. history of smoking more than 10 pack-years; 3. pregnancy.

Design outcomes

Primary

MeasureTime frame
Asthma exacerbation;

Countries

China

Contacts

Public ContactPeng Juan

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

pengjuanxh@126.com+86 15921935216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026